SCHEMBL5111714

SCHEMBL5111714

CC1CNC(c2cccc(F)c2)=N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.51
IDO1 P14902 2/20 0.41
NPY5R Q15761 1/20 0.41
PGR P06401 2/20 0.39
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
CYP17A1 P05093 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
CDC7 O00311 1/20 0.36
ROCK2 O75116 1/20 0.36
MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9579786 0.88 NISCH (0.40) NISCHHTR1AHTR1DHTR2AHTR2C
SCHEMBL108663 0.79 NISCH (0.47) NISCHNPY5RGAA
SCHEMBL1627638 0.77 NISCH (0.37) NISCHHTR1D
SCHEMBL1685395 0.69 NISCH (0.31) NISCH
SCHEMBL1884232 0.69 MEN1 (0.38) NISCHGSK3BESR2
SCHEMBL11835012 0.69 LMNA (0.44) NPY5RPGRADRA2AADRA2BADRA2C
SCHEMBL2491843 0.69 CYP3A4 (0.36) NISCHCYP17A1CYP3A4CYP11B1CYP11B2
SCHEMBL15186733 0.67 NISCH (0.43) NISCHIDO1NPY5RPGRMGAM
SCHEMBL16422068 0.66 NISCH (0.42) NISCHIDO1NPY5RPGRMGAM
SCHEMBL15186777 0.66 NISCH (0.42) NISCHIDO1NPY5RPGRMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326792-B2 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2008-02-05 US disclosed
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers AVENTIS PHARMACEUTICALS INC. (US) 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026916-A1 Heterocyclic compounds as P2X7 ion channel blockers P2RX3, P2RX2, P2RX5 NISCH 1808/4885IDO1 993/4885NPY5R 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.